Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

Leendert H. Zaaijer, Helena C. van Doorn, Marian J. E. Mourits, Marc van Beurden, Joanne A. de Hullu, Muriel A. Adank, Luc R. C. W. van Lonkhuijzen, Hans F. A. Vasen, Brigitte F. M. Slangen, Katja N. Gaarenstroom, Ronald P. Zweemer, Peggy M. L. H. Vencken, Caroline Seynaeve, Mieke Kriege

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)


It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31). Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy
Original languageEnglish
Pages (from-to)1174-1178
JournalBritish journal of cancer
Issue number10
Publication statusPublished - 8 Nov 2016


  • BRCA mutation
  • breast cancer
  • chemotherapy
  • ovarian cancer
  • survival

Cite this